Study Population and Design
neurological deficit, stroke, hemorrhagic stroke, Stroke
STROKE, HEMORRHAGIC STROKE, STROKE
Longitudinal data of the study participants were prospectively collected from the Efficacy of Fluoxetine—a Randomized Controlled Trial in Stroke (EFFECTS), a multicenter, placebo-controlled, double-blind randomized clinical trial that assessed the safety and efficacy of fluoxetine for functional recovery after stroke in 1500 randomized participants from 35 stroke centers and rehabilitation units across Sweden between October 2014 to June 2019.Individuals were eligible to participate in EFFECTS if they were older than 18 years and had a clinical diagnosis of ischemic or hemorrhagic stroke within the past 2 to 15 days and at least 1 persistent neurological deficit.